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Hotspots in Neuro-Oncology
Michael Weller
From the Department of Neurology, University Hospital Zurich, Switzerland
 Radiotherapy and Temozolomide in Ana-
plastic Astrocytoma: A Retrospective
Multicenter Study by the Central Ner-
vous System Study Group of AIRO (Ital-
ian Association of Radiation Oncology)
Scoccianti S, et al. Neuro Oncol 2012; 14: 798–807.
Too many neuro-oncologists change their personal standards
of care over time without adequate support from clinical tri-
als. A classical example for this observation is the increasing
use of temozolomide in addition to radiotherapy in the first-
line treatment of anaplastic astrocytoma. The largest recent
trial in that patient population, the German NOA-04 trial, had
compared radiotherapy alone with alkylating agent chemo-
therapy alone and found no difference between these 2 treat-
ments for any endpoint. In the June issue of Neuro-Oncology,
an Italian consortium reported a retrospective study of 295
patients with newly diagnosed anaplastic astrocytoma treated
from 2002–2007. All patients had received radiotherapy,
67 % received postoperative temozolomide. The majority had
both concomitant and adjuvant temozolomide. The increasing
use of temozolomide over the time frame covered did not pro-
duce an improvement in survival. This interesting analysis
emphasizes the need to base changes in standards of care on
adequate randomized trials. At present, the ongoing
CATNON trial is closest to answering the question of whether
anaplastic astrocytoma patients should be treated with com-
bined modality treatment upfront.
 Clinical and Molecular Characteristics of
Congenital Glioblastoma
Macy ME, et al. Neuro Oncol 2012; 14: 931–41.
In the July issue, a rare variant of glioblastoma, congenital
glioblastoma, was studied and reviewed. The authors reported
an analysis of 5 such patients, 1 died at surgery, the other 4 pa-
tients had adequate tumour control with a median progres-
sion-free survival of 36 months (range: 30–110 months) with
chemotherapy alone. There were no characteristic patterns on
molecular characterization using Affymetrix microarrays and
exhibited expression profiles related both to paediatric and
adult glioblastoma.
 Incidence, Treatment and Survival of
Patients with Craniopharyngioma in the
Surveillance, Epidemiology and End
Results Program
Zacharia BE, et al. Neuro Oncol 2012; 14: 1070–8.
Craniopharyngioma is a rare brain tumour which may occur
in almost any age group and where treatment decisions are
often controversial, specifically regarding the extent of resec-
tion and the role and timing of radiotherapy. In the August is-
sue, Zacharia et al presented an overview of 644 patients with
craniopharyngioma diagnosed between 2004 and 2008 with
data derived from the Surveillance, Epidemiology and End
Results program (SEER) database. One- and 3-year survival
rates were 92 % and 86 %. On multivariate modelling, youn-
ger age, smaller tumours, subtotal resection, and administra-
tion of radiotherapy were favourable prognostic factors,
whereas black race was associated with less favourable out-
come. Altogether, this publication provides a contemporary
overview on the incidence, clinical presentation, and current
patterns of care for this rare brain tumour which may serve
well for the design and conduct of future clinical trials in this
disease.
 Phase II  Trial of Lapatinib in Adult and
Pediatric Patients with Neurofibro-
matosis Type 2 and Progressive
Vestibular Schwannomas
Karajannis MA, et al. Neuro Oncol 2012; 14: 1163–70.
Medical treatment options for patients with neurofibromato-
sis type 2 (NF2) and schwannomas progressing after surgery
and radiotherapy are scarce. In the September issue, Ka-
rajannis et al reported the results of a single-institution phase-
II study to assess the response of patients affected by these
tumours to lapatinib, a reversible inhibitor of epidermal
growth factor receptor and ErbB2. Response was defined as a
> 15-% decrease in tumour volume. This endpoint was evalu-
able in 17 patients. Hearing performance was available as a
secondary endpoint in 13 patients. Four of 17 available pa-
tients showed an objective response with a median time to re-
sponse of 4.5 months. Four of 13 patients available for hear-
ing had a response, too. Toxicity was in general minor and no
modifications of the dose of 900 mg/m2 twice daily (paediat-
ric patients), respectively 1500 mg flat daily for adult patients
were made. Overall, this study demonstrates some objective
activity of lapatinib in NF2 patients with progressive vestibu-
lar schwannomas. While this efficacy is limited, it adds to the
current repertoire of pharmacological agents with some ben-
efit in these patients that are notoriously difficult to treat.
Combinations of lapatinib with vascular endothelial growth
factor antagonists seem to be the next step.
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